BioCentury | Jan 5, 2019

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Innovations | May 1, 2018
Distillery Therapeutics


INDICATION: Spinal muscular atrophy (SMA) Cell culture and mouse studies suggest inhibiting SQSTM1 could help treat SMA, which is caused by SMN1 mutations. In motor neuron cells derived from a mouse model of SMA or...
BC Week In Review | Aug 11, 2017
Clinical News

Soligenix begins Phase III of dusquetide to treat oral mucositis

Soligenix Inc. (NASDAQ:SNGX) began the Phase III IDR-OM-02 (DOM-INNATE) trial of dusquetide (SGX94, SGX942) to treat severe oral mucositis (OM) in about 190 patients undergoing chemoradiation therapy (CRT) for head and neck cancer. Patients receive...
BC Week In Review | Dec 14, 2016
Clinical News

Dusquetide regulatory update

The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) granted promising innovative medicine (PIM) designation to dusquetide from Soligenix to treat severe oral mucositis in head and neck cancer patients receiving chemoradiation therapy. Dusquetide is...
BC Week In Review | Sep 19, 2016
Company News

Soligenix, SciClone deal

The partners added commercialization and development rights in Taiwan, South Korea and Vietnam to a 2013 deal granting SciClone rights to develop and market SGX942 in China, including Hong Kong and Macau, to treat oral...
BC Week In Review | Jan 4, 2016
Clinical News

SGX94: Preliminary Phase II data

Preliminary data from a double-blind, placebo-controlled, U.S. Phase II trial in 111 patients undergoing chemoradiation for head and neck cancer showed that 1.5 mg/kg IV SGX942 reduced the median duration of severe oral mucositis by...
BC Week In Review | Sep 28, 2015
Clinical News

SGX94: Completed Phase II enrollment

Soligenix completed enrollment of about 95 patients undergoing chemoradiation therapy for head and neck cancer in a double-blind, placebo-controlled, U.S. Phase II trial evaluating 1.5, 3 and 6 mg/kg IV SGX942. Soligenix Inc. (OTCBB:SNGX), Princeton,...
BC Week In Review | Dec 16, 2013
Clinical News

SGX94: Phase II started

Soligenix began a double-blind, placebo-controlled Phase II trial to evaluate SGX942 in patients undergoing chemoradiation therapy for head and neck cancer. SGX942 has Fast Track designation to treat OM as a result of radiation or...
BC Week In Review | Sep 23, 2013
Clinical News

SGX94 regulatory update

FDA granted Orphan Drug designation to Soligenix's SGX94 to treat acute radiation syndrome (ARS). Soligenix said preclinical data with SGX94 showed the potential to mitigate damage to the skin and gastrointestinal tract, and enable clearance...
BC Week In Review | Jul 15, 2013
Company News

SciClone, Soligenix deal

Soligenix granted SciClone Chinese marketing rights to SGX942 to treat oral mucositis (OM). In exchange, SciClone granted Soligenix access to SciClone's clinical and regulatory data library, including Phase II studies of SCV-07 to treat OM....
Items per page:
1 - 10 of 13